Roche Holding AG
RHHBF
Get informed when a big investor buys or sells
+ FollowMarket Cap$365.01B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
Group sales increased by 8% in the first half of the year, excluding COVID impact.
Pharma division saw strong growth in base business with an 8% increase in sales.
Diagnostics division also experienced solid growth with a 9% increase in sales.
Exclusive for Stockcircle Pro members
Sign up
$487.85
7% upside
Current Fair Value
7% upsideUndervalued by 7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $365.01 Billion |
|---|---|
| Enterprise Value | $391.22 Billion |
| Dividend Yield | $12.41 (2.67%) |
| Earnings per Share | $16.19 |
| Beta | 0.35 |
| Outstanding Shares | 809,257,000 |
Return
| Return on Equity | 66.85% |
|---|---|
| Return on Assets | 22.26% |
| Return on Invested Capital | 42.92% |
Valuation & Multiples
| P/E Ratio | 23.91 |
|---|---|
| PEG | -306.77 |
| Price to Sales | 3.0 |
| Price to Book Ratio | 10.13 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | 13.22 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$12.51
Average shareholder expectationRevenue Estimate
$37.65 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Roche Holding AG
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...